Segments - Schedule of Drug Development Segment and Reconciliation to Consolidated Net (Loss) Income Segment Operations (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|||
| Segment Reporting Information [Line Items] | ||||
| Total revenue | $ 0 | $ 257 | ||
| Clinical expense | 2,015 | 1,712 | ||
| Preclinical expense | 247 | 937 | ||
| Chemistry, manufacturing, and controls | 555 | 500 | ||
| IPR&D expense | 12,351 | 5,141 | ||
| Selling, general and administrative | 4,588 | 3,726 | ||
| Interest expense | 0 | 173 | ||
| Interest income | (535) | (776) | ||
| Other segment expense (income) | [1] | 6,429 | (624) | |
| Segment net loss | (21,299) | (5,391) | ||
| Adjustments and reconciling items | 0 | 0 | ||
| Net loss | (21,299) | (5,391) | ||
| In process research and development | ||||
| Segment Reporting Information [Line Items] | ||||
| IPR&D expense | $ 8,000 | $ 0 | ||
| ||||
| X | ||||||||||
- Definition Chemistry manufacturing and controls expense. No definition available.
|
| X | ||||||||||
- Definition Clinical expense. No definition available.
|
| X | ||||||||||
- Definition Net income loss before adjustments. No definition available.
|
| X | ||||||||||
- Definition Other segment income expense. No definition available.
|
| X | ||||||||||
- Definition Preclinical expense. No definition available.
|
| X | ||||||||||
- Definition Reconciliation of segment net loss income adjustments. No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|